Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 19/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25405202 | 1.00 | LTA4H (0.40) | LTA4HCYP11B1CYP11B2 | |
| SCHEMBL30275367 | 0.80 | CYP11B1 (0.39) | CYP11B1CYP11B2 | |
| SCHEMBL23980935 | 0.80 | CYP11B1 (0.39) | CYP11B1CYP11B2 | |
| SCHEMBL30911904 | 0.78 | LTA4H (0.38) | LTA4HCYP11B1CYP11B2 | |
| SCHEMBL29393223 | 0.78 | LTA4H (0.60) | LTA4H | |
| SCHEMBL25240826 | 0.75 | SIRT1 (0.36) | — | |
| Hydrochloric Acid SCHEMBL30416305 | 0.75 | LTA4H (0.50) | LTA4H | |
| SCHEMBL23980911 | 0.75 | HTR3A (0.41) | LTA4H | |
| Hydrochloric Acid SCHEMBL25236291 | 0.74 | HTR3A (0.40) | LTA4H | |
| SCHEMBL23981032 | 0.74 | LTA4H (0.40) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552791-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4638440-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4143183-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250214999-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2024131869-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4143183-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021219019-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | LTA4H 831/4885CYP11B1 970/4885CYP11B2 1576/4885 |
| US-12552791-B2 | Heterocyclic GLP-1 agonists | GLP1R, NPY1R, NPY2R | LTA4H 2743/4885CYP11B1 474/4885CYP11B2 648/4885 |
| US-20250214999-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | LTA4H 831/4885CYP11B1 970/4885CYP11B2 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.